Want to join the conversation?
Boston, Massachusetts-based $VRTX said that it expects to increase the number of people eligible for Kalydeco and Orkambi drugs in 2016 through label expansion efforts. $VRTX added that it is awaiting for US FDA's approval of cystic fibrosis drug Kalydeco in people with CF ages 2 and older who have certain residual function mutations.
Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.
Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.
$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.